In another prospective study of 68 patients with midgut carcinoid tumors metastatic to the liver, with prior primary tumor resection [17], participants were randomized to receive octreotide (2–3x daily) or octreotide and IFN-a (3–5 times weekly). The gene discussed is IFNA1; the disease is neoplasm.